Ultomiris Market Trends, Growth Drivers, and Future Outlook (2026–2033)
Ultomiris  Drug (ravulizumab) Market  is a long-acting monoclonal antibody developed to treat rare complement-mediated disorders. As a C5 complement inhibitor, it plays a critical role in managing diseases such as paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder...
0 Commentarios 0 Acciones 12 Views 0 Vista previa